Tianjin Chase Sun Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The Company also provides medical apparatus and instrument. The Company distributes its products in domestic market and to overseas markets.

Employees

0

Sector

Pharmaceuticals

Calendar

2025-03-27 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-10	4.210 ¥	+0.96%	55,064,170
24-12-10	4.170 ¥	-0.71%	76,984,890
24-12-09	4.200 ¥	-0.71%	77,429,610
24-12-06	4.230 ¥	+0.95%	93,094,400
24-12-05	4.190 ¥	+0.48%	51,935,010

End-of-day quote Shenzhen S.E., December 09, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart TIANJIN-CHASE-SUN-PHARMAC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

4.170CNY

Average target price

4.000CNY

Spread / Average Target

-4.08%

Consensus

Profit revisions

estimates-change-chart TIANJIN-CHASE-SUN-PHARMAC

Estimate revisions

Annual profits - Rate of surprise

quality-estimates-chart TIANJIN-CHASE-SUN-PHARMAC

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2024-12-11			5-day change	1st Jan Change
4.210 ^CNY	+0.96%		+1.45%	-0.71%

Oct. 24	Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
Aug. 29	Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Capitalization	12.53B 1.73B 1.64B 1.52B 1.36B 2.45B 147B 2.71B 18.97B 7B 60.19B 6.48B 6.34B 263B	P/E ratio 2024 *	23.2x	P/E ratio 2025 *	21.9x
Enterprise value	12.53B 1.73B 1.64B 1.52B 1.36B 2.45B 147B 2.71B 18.97B 7B 60.19B 6.48B 6.34B 263B	EV / Sales 2024 *	2.02x	EV / Sales 2025 *	1.92x
Free-Float	59.17%	Yield 2024 *	-	Yield 2025 *	-

Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024	Oct. 24	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 29	CI
Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue	Feb. 29	MT
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Tianjin Chase Sun Pharma’s Muscle Relaxant Passes Drug Consistency Test	23-09-22	MT
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-27	CI

1 day	-0.71%
1 week	+0.48%
Current month	+2.71%
1 month	-3.70%
3 months	+31.55%
6 months	+21.57%
Current year	-1.65%

Tianjin Chase Sun Pharmaceutical Co.,Ltd Stock

Equities

300026

CNE100000GF1

Pharmaceuticals

Valuation: Tianjin Chase Sun Pharmaceutical Co.,Ltd

Chart: Tianjin Chase Sun Pharmaceutical Co.,Ltd

Latest news: Tianjin Chase Sun Pharmaceutical Co.,Ltd

Press Releases: Tianjin Chase Sun Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Tianjin Chase Sun Pharmaceutical Co.,Ltd

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Annual profits - Rate of surprise

Director	Title	Age	Since
Wu Jun Lan CEO	Chief Executive Officer	49	2024-03-31
Wu Sun DFI	Director of Finance/CFO	55	2024-03-31
Chun Xu Li PRN	Corporate Officer/Principal	54	2019-04-25

Manager	Title	Age	Since
Wu Jun Lan BRD	Director/Board Member	49	2019-04-23
Dan Liang BRD	Director/Board Member	43	2013-04-15
Sheng Tian Wang BRD	Director/Board Member	73	2017-12-27

	2024 *	2025 *
Net sales	6.19B 854M 813M 753M 670M 1.21B 72.47B 1.34B 9.38B 3.46B 29.76B 3.21B 3.14B 130B	6.51B 898M 854M 792M 704M 1.27B 76.18B 1.41B 9.86B 3.64B 31.28B 3.37B 3.3B 137B
Net income	533M 73.49M 69.95M 64.82M 57.65M 104M 6.24B 115M 807M 298M 2.56B 276M 270M 11.17B	557M 76.8M 73.1M 67.74M 60.25M 109M 6.52B 121M 843M 311M 2.68B 288M 282M 11.68B
Net Debt	-	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-0.71%	+0.48%	-4.58%	-2.80%	1.73B
DONG-E-E-JIAO CO.,LTD.	+1.18%	-0.29%	+15.80%	+28.59%	5.15B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-0.18%	-1.63%	-32.12%	+2.48%	3.9B
TASLY PHARMACEUTICAL GROUP CO., LTD	+0.42%	-1.43%	-7.94%	+3.95%	2.98B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+1.11%	-0.90%	-7.63%	+21.74%	2.94B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.29%	+0.12%	-3.13%	-9.03%	2.5B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+0.32%	-3.81%	+30.33%	+67.96%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	-1.50%	-4.15%	-17.10%	1.64B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-1.15%	-4.90%	+65.58%	+103.11%	1.54B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	+0.35%	-0.25%	-31.57%	-43.81%	1.34B
Average	+0.17%	-0.81%	+2.06%	+15.51%	2.54B
Weighted average by Cap.	+0.35%	-0.54%	-0.09%	+15.44%